American Heart Association Scientific Sessions 2022
Among the highlights of the American Heart Association’s annual scientific meeting (5-7 November, Chicago, Illinois, USA) were full results from the PROMINENT trial of triglyceride (TG) lowering with pemafibrate to reduce cardiovascular (CV) risk, latest updates on links between remnant cholesterol and atherosclerotic cardiovascular disease (ASCVD), and Mendelian randomisation studies of ANGPTL3 and TG levels in relation to cardiometabolic and liver diseases and acute pancreatitis.
Read More > American Heart Association Scientific Sessions 2022